Scarica l'app Stockscreener
72.86
1.43%
-1.06
Dopo l'orario di chiusura:
72.25
-0.61
-0.84%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$73.92
Aprire:
$73.05
Volume 24 ore:
5.20M
Relative Volume:
0.85
Capitalizzazione di mercato:
$28.42B
Reddito:
$4.30B
Utile/perdita netta:
$571.50M
Rapporto P/E:
51.00
EPS:
1.4285
Flusso di cassa netto:
$570.80M
1 W Prestazione:
+4.77%
1M Prestazione:
+8.97%
6M Prestazione:
-15.70%
1 anno Prestazione:
-16.92%
Intervallo 1D:
$71.66
$73.53
Intervallo di 1 settimana:
$68.54
$75.97
Portata 52W:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
72.86 | 28.83B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
107.42 | 188.86B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.51 | 135.38B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.04 | 137.16B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.88 | 129.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.65 | 49.00B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-12 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
DexCom Inc (DXCM) Trading 4.47% Higher on Jan 22 - GuruFocus
Campbell & CO Investment Adviser LLC Has $629,000 Holdings in DexCom, Inc. $DXCM - MarketBeat
Allstate Corp Invests $964,000 in DexCom, Inc. $DXCM - MarketBeat
Dexcom Reports 22% Revenue Growth to $1.2 Billion in 2024 Amidst Challenges - Intellectia AI
Analysts Offer Insights on Healthcare Companies: BillionToOne, Inc. Class A (BLLN) and Dexcom (DXCM) - The Globe and Mail
FDA Flags Serious Software Issue in Dexcom Glucose Monitoring App - Drugwatch.com
Analysts Are Bullish on Top Healthcare Stocks: Dexcom (DXCM), AbbVie (ABBV) - The Globe and Mail
DexCom Inc. (NASDAQ:DXCM) Combines Strong Fundamentals with Bullish Chart Pattern - Chartmill
Fisher Funds Management LTD Sells 91,159 Shares of DexCom, Inc. $DXCM - MarketBeat
Market Pulse: Can DexCom Inc be the next market leader2025 Technical Patterns & Detailed Earnings Play Strategies - baoquankhu1.vn
Dexcom (DXCM) releases preliminary, unaudited results for Q4 2025 - MSN
Is Dexcom the Next Sleeper Stock? The Real Talk on This Glucose Tech Giant - AD HOC NEWS
DexCom, Inc. $DXCM Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Pinnacle Financial Partners Inc Sells 33,980 Shares of DexCom, Inc. $DXCM - MarketBeat
Stephens Investment Management Group LLC Sells 16,732 Shares of DexCom, Inc. $DXCM - MarketBeat
Nordea Investment Management AB Boosts Stake in DexCom, Inc. $DXCM - MarketBeat
Is DexCom Stock Underperforming the S&P 500? - MSN
DexCom Stock Declines Following Strong Preliminary Q4 Results - Yahoo Finance
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now - TradingView — Track All Markets
MGO One Seven LLC Buys 14,699 Shares of DexCom, Inc. $DXCM - MarketBeat
How Do Investors Really Feel About DexCom Inc? - Benzinga
Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
Dexcom CEO Talks G8 CGM Sensor - Medical Device and Diagnostic industry
Palmetto Grain Brokerage - Palmetto Grain Brokerage
DexCom's Q4 2025 Earnings: What to Expect - Yahoo Finance
Dexcom’s new CEO talks affordability, over-the-counter glucose sensors - Healthcare Brew
New Dexcom CEO Jake Leach talks 2026 roadmap, next-gen tech - MassDevice
DexCom (DXCM) Releases Preliminary, Unaudited Results for Q4 2025 - Insider Monkey
Dexcom’s Jake Leach on the future of continuous glucose monitoring - Modern Healthcare
Is DexCom (DXCM) Pricing Justified After Recent Multi Year Share Price Weakness - Yahoo Finance
RWC Asset Management LLP Cuts Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Shares Bought by PKO Investment Management Joint Stock Co - MarketBeat
JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth - Yahoo Finance
GRIMES & Co WEALTH MANAGEMENT LLC Sells 17,554 Shares of DexCom, Inc. $DXCM - MarketBeat
Dexcom reports 13% revenue growth in Q4, reiterates 2025 guidance By Investing.com - Investing.com Nigeria
Barclays Downgrades DexCom (DXCM), Lowers Price Target to $71.00 - GuruFocus
Why This Medical Device Company Is the Top Stock in the S&P 500 Today - Barron's
Dexcom reports 13% rise in preliminary Q4 revenue, issues 2026 outlook - MSN
Why DexCom Is the Top Stock in the S&P 500 Today - Barron's
Barclays Downgrades DexCom to Underweight From Equal Weight, Adjusts Price Target to $71 From $80 - marketscreener.com
DexCom (DXCM) Reports Strong Preliminary Q4 and FY 2025 Revenue Growth - GuruFocus
Dexcom Updates Fiscal 2025 Revenue Guidance; Sets 2026 Outlook - marketscreener.com
Dexcom reports 13% revenue growth in Q4, reiterates 2025 guidance - Investing.com
(DXCM) DexCom Expects 2026 Total Revenue Range $5.16B$5.25B, vs. FactSet Est of $5.23B - marketscreener.com
Glucose monitor maker Dexcom's prelim Q4 revenue beats expectations on G7 15 Day launch - TradingView — Track All Markets
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook - Business Wire
Assessing DexCom (DXCM) Valuation As Analyst Actions And Conference Spotlight Shape Sentiment - simplywall.st
DexCom (DXCM) Price Target Raised by Bernstein | DXCM Stock News - GuruFocus
Mizuho Adjusts Price Target on DexCom to $78 From $75, Maintains Outperform Rating - marketscreener.com
Bernstein Adjusts Price Target on DexCom to $86 From $84, Maintains Outperform Rating - marketscreener.com
Robeco Institutional Asset Management B.V. Lowers Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):